Nothing said here yet.
to join the conversation.
| Boughton SoleilChief Legal Officer | Sell | 3,462 | $95.6K | Wed, Oct 28 |
| Boughton SoleilChief Legal Officer | Sell | 3,461 | $100.6K | Wed, Oct 14 |
| Okupe OluyemiChief Financial Officer | Sell | 2,000 | $59.4K | Thu, Oct 1 |
| Boughton SoleilChief Legal Officer | Sell | 3,461 | $101.0K | Wed, Sep 30 |
| Okupe OluyemiChief Financial Officer | Sell | 29,277 | $876.8K | Tue, Sep 22 |
| Okupe OluyemiChief Financial Officer | Sell | 12,313 | $354.9K | Thu, Sep 17 |
| Boughton SoleilChief Legal Officer | Sell | 6,236 | $173.7K | Wed, Sep 16 |
| Chi MichaelChief Operating Officer | Sell | 14,027 | $398.2K | Tue, Sep 15 |
| Elshenawy MohamedCTO | Sell | 7,954 | $225.8K | Tue, Sep 15 |
| Boughton SoleilChief Legal Officer | Sell | 3,458 | $98.0K | Wed, Sep 2 |
| Boughton SoleilChief Legal Officer | Sell | 25,111 | $691.8K | Wed, Aug 19 |
| Okupe OluyemiChief Financial Officer | Sell | 4,938 | $148.1K | Wed, Aug 19 |
HHS said it will not go after state-licensed pharmacies, federal facilities, or licensed doctors for compounding six peptides—BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500.
Hims stock popped Wednesday after RFK Jr. circumvented the FDA, giving a green light to some unapproved peptides.
Key TakeawaysHims & Hers shares rose 6% today after HHS said it won’t act against qualifying pharmacies compounding six unapproved peptides while it writes a formal rule.
For questions about this article or underlying research, email [email protected].
If you only glanced at the headlines on Hims & Hers Health, the story looked exciting. AI-native care, GLP-1 partnerships and global expansion sounded like the textbook setup for a win.
Hims & Hers Health (NYSE:HIMS) announced its largest men's health expansion with new injectable and oral testosterone replacement therapies.
In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $27.71, marking a -4.87% move from the previous day.
Hims & Hers Health (HIMS) asked a federal judge in California to toss out a Federal Trade Commission
Key Stats for Hims & Hers StockCurrent Price: $29.
Hims argued that the agency ignored the company’s disclosures and misapplied federal law on subscriptions and privacy.